Aug 23 (Reuters) - Eli Lilly's treatment for early Alzheimer's is expected to be blocked for use by Britain's National Health Service $(NHS)$, The Telegraph reported on Friday.
The drug donanemab would be rejected by the National Institute for Health and Care Excellence $(NICE)$, which decides what drugs are available on the NHS, the newspaper reported citing insiders.
(Reporting by Nilutpal Timsina in Bengaluru)
((Nilutpal.Timsina@thomsonreuters.com; +91 86382 04706;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments